News Preview
Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm
Generate Biomedicines (GNMN) has a strong intellectual property moat, according to a Wall Street analyst. The analyst believes that the company's dosing interval is a key competitive advantage.
Want to stay up to date with the world events at sea or at home?
Explore Navvyx News - the best News app for seafarers.